Yuanhui Sun

Yuanhui Sun

Auto-generated profile, based on publicly available information

Yuanhui Sun

Huazhong Agricultural University National Key Laboratory of Crop Genetic Improvement, Hubei Hongshan Laboratory Wuhan 430070

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2025 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
YSYuanhui Sun
Yuanhui Sun
ZZZhixian Zhu
Zhixian Zhu
QZQiangwei Zhou
Qiangwei Zhou
ZWZhe Wang
Zhe Wang
YHYuying Hou
Yuying Hou
Guoliang LiGuoliang Li
Guoliang Li
Cancer is a major global health threat, and early detection is crucial for improving patient outcomes. DNA methylation in circulating cell-free DNA (cfDNA) has emerged as a promising biomarker for non-invasive cancer diagnosis. However, the integration and utilization of existing cfDNA methylation data have been limited, hindering comprehensive research efforts, particularly in the discovery of cfDNA methylation biomarkers. To address this challenge, we introduce cfMethDB, a comprehensive database dedicated to cfDNA methylation in cancer that encompasses 4828 publicly available datasets. Through standardized analysis, we identified 1,048,770 differentially methylated cytosines (DMCs) as candidate biomarkers across seven cancer types. With cfMethDB, we not only identified known cfDNA methylation biomarkers, but also discovered several genes, such as ZIC4, that could be novel biomarkers. Moreover, cfMethDB offers a suite of user-friendly tools, including biomarker evaluation, pan-cancer search, and end motif analysis. We hope that cfMethDB will serve as a valuable platform for the discovery of novel cancer cfDNA methylation biomarkers and will facilitate cancer research and clinical applications. cfMethDB is publicly available at: https://cfmethdb.hzau.edu.cn/home.

19 March 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
YSYuanhui Sun
Yuanhui Sun
ZZZhixian Zhu
Zhixian Zhu
QZQiangwei Zhou
Qiangwei Zhou
ZWZhe Wang
Zhe Wang
YHYuying Hou
Yuying Hou
Guoliang LiGuoliang Li
Guoliang Li
Cancer is a major global health threat, and early detection of cancer is crucial for improving patient outcomes. DNA methylation in circulating cell-free DNA (cfDNA) has emerged as a promising biomarker for non-invasive cancer diagnosis. However, the integration and utilization of existing cfDNA methylation data have been limited, hindering comprehensive research efforts, especially in the discovery of cfDNA methylation biomarkers. To address this challenge, we introduce cfMethDB, a comprehensive database dedicated to cfDNA methylation in cancer that encompasses 4828 publicly available datasets. Through standardized analysis, we identified 1,048,770 differentially methylated cytosines (DMCs) as candidate biomarkers across seven cancer types. With cfMethDB, we not only identified known cfDNA methylation biomarkers, but also discovered several genes, such as ZIC4 , that could be novel biomarkers. Moreover, cfMethDB offers a suite of user-friendly tools, including biomarker evaluation, pan-cancer search and end motif analysis. We hope that cfMethDB will serve as a valuable platform for the discovery of novel cancer cfDNA methylation biomarkers and will facilitate cancer research and clinical applications. cfMethDB is publicly available at: https://cfmethdb.hzau.edu.cn/home .

11 November 2026 in Nucleic Acids Research
Verified
Journal Article
Open access
YSYuanhui Sun
Yuanhui Sun
ZPZongyang Peng
Zongyang Peng
LZLinyun Zhong
Linyun Zhong
ZLZihe Li
Zihe Li
YHYunzhao Hao
Yunzhao Hao
Guoliang LiGuoliang Li
Guoliang Li
Cancer-associated differentially methylated regions (DMRs) are promising biomarkers for cancer diagnosis, prognosis, and therapeutic response, but their biological significance and potential applications remain to be systematically explored across datasets. To support this, we released MethMarkerDB 2.0 (https://methmarkerdb.hzau.edu.cn/v2), which provides several improvements over the previous version: (i) Expands the data resource from 13 to 21 cancer types and from 658 to 1236 whole-genome methylome samples, comprising ∼5.6 million candidate DMRs and 6411 literature-curated biomarker records.(ii) Integrates 450K DNA methylation data from The Cancer Genome Atlas and Epigenome-Wide Association Study Atlas and transcript annotations into the “MethMarker Gene Search” module. These data provide complementary evidence from independent datasets and platforms and allow users to examine CpG-level information for individual DMRs. Additionally, cell-type-resolved reference methylation data allow users to check cellular-background methylation. (iii) Introduces four analysis modules to characterize DMR methylation patterns across age groups and spatial ecotypes, and connect DMRs with transcription factor binding evidence and cancer cell-line drug responses. Moreover, the “Methylation-Cas Designer” supports guide RNA design for methylation-sensitive restriction enzyme–Cas assays and targeted epigenome editing. In summary, MethMarkerDB 2.0 provides expanded resources, diverse functional analyses, and experimental design tools, facilitating the interpretation and application of cancer-associated DMRs.